New NASDAQ Alert [Inside]

AwesomeStocks Hello! New Alert: 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) SXTP is a newly listed NASDAQ company that just had its IPO last month. Following its IPO in July, SXTP traded as high as 8.65. That is more than 420% above yesterday’s close of just 1.66. Over the past few weeks SXTP has been consolidating, but Friday and Monday formed what could be the start of a bullish breakout higher. SXTP could present a breakout opportunity with a chart setup suggesting the potential for increased gains. The last time one of our alerts had a similar chart pattern, it experienced incredible gains. In addition, SXTP released big news this morning that could be a significant growth catalyst for the company. Here is the announcement from this morning: - “60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov” SXTP is a “pharmaceutical company focused on developing new medicines for infectious diseases”. SXTP specializes in “developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people”. SXTP “achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018”. “Malaria is a life-threatening disease when contracted by malaria-naïve individuals.” “According to the World Malaria Report 2020, there were 241 million cases of malaria globally in 2020”. Sadly, according to the CDC, “In 2020, an estimated 627,000 people died of malaria”. Within the “last decade, increasing numbers of partners and resources have rapidly increased malaria control efforts”. “This scale-up of interventions has saved millions of lives globally and cut malaria mortality by 36% from 2010 to 2020, leading to hopes and plans for elimination and ultimately eradication”. However, as SXTP explains: “There are no vaccines approved to prevent malaria in malaria-naïve travelers so public health agencies recommend the use of malaria chemoprophylactic drugs.” Furthermore: “Most travelers from Canada and the United States to tropical countries are malaria-naïve and malaria is life-threatening if contracted.” “Tafenoquine is the active molecule in the Company’s U.S. Food and Drug Administration-approved regimen for malaria prevention, ARAKODA®.” “ARAKODA, an oral tablet containing 100 mg of tafenoquine base, is an anti-malarial indicated in the U.S. for the prophylaxis of malaria in individuals aged 18 years and older.” In addition, as the company states: “The ARAKODA regimen of tafenoquine has exhibited positive Phase II study data in patients with mild-moderate COVID-19 disease.” SXTP also “collaborates with prominent research organizations in the U.S., Australia and Singapore”. The company’s “mission has been supported through in-kind funding from the United States Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company”. SXTP is “headquartered in Washington D.C., with a majority-owned subsidiary in Australia”. Now, investors are getting an opportunity to own this company for the very first time following their NASDAQ IPO last month. On July 14, the company announced: - “60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering” Following the IPO, the company announced a big accomplishment: “60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects” Here are the highlights from this press release: - “Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.” - “Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’ USFDA-approved drug for malaria prevention, ARAKODA®.” As the company further explains: “announced that the Canadian Intellectual Property Office (CIPO) has issued the Company a patent covering the use of novel regimens of tafenoquine for the prevention of malaria in malaria-naive individuals. “Travelers from, and residents of, Canada and the United States, are usually malaria naïve because they have not previously contracted malaria and thus lack immunity to the disease.” Importantly: “The newly issued Canadian patent provides exclusive use of tafenoquine for preventing malaria in malaria-naive patients in Canada to December 2, 2035.” “The Company was previously issued a U.S. patent covering the use of tafenoquine for malaria prevention in malaria-naïve individuals.” “The U.S. and Canadian patents cover the ARAKODA dosing regimen approved in the U.S. for malaria prevention.” In addition, SXTP released breaking news this morning: - “60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov” SXTP has multiple potential catalysts in its favor to experience high growth. Make sure to do your own due diligence. Sources: [WHO]( [CDC]( [PR1]( [PR2]( [PR3]( [PR4]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 8/11/23 for the distribution of this advertisement about SXTP dated 8/15/23. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](